Neurocrine Biosciences Inc (NBIX) released positive topline data from the Phase 3 CAHtalyst Pediatric Study of crinecerfont in children and adolescents with classic congenital adrenal hyperplasia (CAH). The study met its primary endpoint, demonstrating a significant decrease in serum androstenedione from baseline at Week 4 versus placebo. Approximately 30% of participants receiving crinecerfont achieved a reduction to a physiologic GC dose while maintaining androgen control compared to 0% of participants receiving a placebo. NBIX shares are up 3.74% at $114.83.